Shopping Cart
Remove All
Your shopping cart is currently empty
Elipovimab
😃Good
Catalog No. T77177Cas No. 2101210-43-7
Elipovimab (GS-9722) is a humanized broadly neutralizing antibody (bNAb) targeting the V3 glycan supersite of the HIV-1 envelope glycoprotein gp120. As an Fc-optimized version of PGT121, it neutralizes viral particles and eliminates infected cells via antibody-dependent cellular cytotoxicity (ADCC). The antibody exhibits enhanced effector cell-mediated killing activity in the presence of TLR agonists.
Elipovimab
Elipovimab
😃Good
Catalog No. T77177Cas No. 2101210-43-7
Elipovimab (GS-9722) is a humanized broadly neutralizing antibody (bNAb) targeting the V3 glycan supersite of the HIV-1 envelope glycoprotein gp120. As an Fc-optimized version of PGT121, it neutralizes viral particles and eliminates infected cells via antibody-dependent cellular cytotoxicity (ADCC). The antibody exhibits enhanced effector cell-mediated killing activity in the presence of TLR agonists.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $622 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $996 | 2-4 weeks | 2-4 weeks |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Elipovimab (GS-9722) is a humanized broadly neutralizing antibody (bNAb) targeting the V3 glycan supersite of the HIV-1 envelope glycoprotein gp120. As an Fc-optimized version of PGT121, it neutralizes viral particles and eliminates infected cells via antibody-dependent cellular cytotoxicity (ADCC). The antibody exhibits enhanced effector cell-mediated killing activity in the presence of TLR agonists. |
| In vitro | In ex vivo assays using PBMCs from HIV-infected individuals, Elipovimab (GS-9722) demonstrates potent ADCC activity against cells expressing viral envelopes. Pre-treatment of NK cells with TLR7 or TLR9 agonists significantly increases Elipovimab-mediated killing of autologous HIV-infected CD4+ T cells and promotes more efficient target cell clearance [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | HIV-1 |
| Cas No. | 2101210-43-7 |
| Isotype | IgG1-ADLEEMLS |
| Storage | Lyophilized powder: -20~-80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Elipovimab | purchase Elipovimab | Elipovimab cost | order Elipovimab | Elipovimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.